Ignite Creation Date:
2024-05-06 @ 8:33 AM
Last Modification Date:
2024-10-26 @ 12:02 PM
Study NCT ID:
NCT02767752
Status:
TERMINATED
Last Update Posted:
2018-07-10
First Post:
2016-05-06
Brief Title:
Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer
Sponsor:
Herlev Hospital
Organization:
Herlev Hospital
Study Overview
Official Title:
A Single Center Randomized Double-Blind Placebo-Controlled Phase 2 Study of Gemcitabine GEM and Capecitabine CAP With or Without T-ChOS as Adjuvant Therapy in Patients With Surgically Resected Pancreatic Cancer
Status:
TERMINATED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Poor accrual and change of SOC FOLFIRINOX in adjuvant setting
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CHIPAC
Brief Summary:
This is a single center randomized double-blind placebo-controlled phase II trial that will compare the efficacy of T-ChOS in combination with gemcitabine to gemcitabine alone as adjuvant treatment for 6 months in patients with surgically resected pancreatic adenocarcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None